Kinarus AG is a clinical-stage pharmaceutical company focused on bringing novel treatments to patients suffering from viral, respiratory, and ophthalmic diseases. Kinarus’s unique and innovative combinatorial therapeutic candidate has broad potential to transform numerous therapeutic areas.

New dimensions toward effective therapies

Kinarus is a clinical-stage biopharmaceutical company focused on bringing novel, patient-focused treatments to those suffering from viral, respiratory, and ophthalmic diseases.

Kinarus was incorporated as a private company in Basel, Switzerland in 2017. Its therapeutic drug candidate, KIN001, consists of an advanced clinical stage p38 MAPK inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life.

Recently, in response to the global challenge of COVID-19, Kinarus has initiated clinical evaluation of its combination therapy to treat patients suffering from SARS-CoV-2 infection. Kinarus has discovered that KIN001 has anti-viral activity against SARS-CoV-2, including against its variants of concern. KIN001 also possesses anti-inflammatory and anti-fibrotic activity. These multiple mechanisms of KIN001 suggest its potential to address both acute and long-term consequences of COVID-19.

The composition of KIN001 is patent protected in the US, EU, China, and other countries. Patent protection extends to at least 2037.

icon2.svg

AMD

Age-Related Macular Degeneration

> read more

icon3.svg

COVID-19

Coronavirus disease 19

> read more

icon1.svg

IPF

Idiopathic Pulmonary Fibrosis

> read more